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Lymphodepleting regimens are used before adoptive immuno-
therapy to augment the antitumor efficacy of transferred T cells by
removing endogenous homeostatic “cytokine sinks.” These condi-
tioning modalities, however, are often associated with severe tox-
icities. We found that microRNA-155 (miR-155) enabled tumor-
specific CD8+ T cells to mediate profound antitumor responses in
lymphoreplete hosts that were not potentiated by immune-abla-
tion. miR-155 enhanced T-cell responsiveness to limited amounts
of homeostatic γc cytokines, resulting in delayed cellular contraction
and sustained cytokine production. miR-155 restrained the expres-
sion of the inositol 5-phosphatase Ship1, an inhibitor of the serine-
threonine protein kinase Akt, and multiple negative regulators of
signal transducer and activator of transcription 5 (Stat5), including
suppressor of cytokine signaling 1 (Socs1) and the protein tyrosine
phosphatase Ptpn2. Expression of constitutively active Stat5a reca-
pitulated the survival advantages conferred by miR-155, whereas
constitutive Akt activation promoted sustained effector functions.
Our results indicate that overexpression of miR-155 in tumor-
specific T cells can be used to increase the effectiveness of adop-
tive immunotherapies in a cell-intrinsic manner without the need
for life-threatening, lymphodepleting maneuvers.
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Adoptive T-cell–based immunotherapy is a potent and ef-fective treatment for patients with advanced cancer (1, 2).
Lymphodepleting preconditioning regimens and high-dose in-
terleukin 2 (IL-2) are routinely used to enhance the engraftment
and antitumor function of transferred T cells (2). Lympho-
depletion enhances T-cell–based immunotherapies by eliminating
immunosuppressive CD25+FOXP3+ regulatory T (Treg) cells (3,
4) and activating antigen-presenting cells through Toll-like re-
ceptor signaling (5). Perhaps most important, lymphodepletion
removes endogenous cellular cytokine sinks, thus increasing the
availability of homeostatic cytokines that support the prolife-
ration and function of transferred cells (6).
Mouse studies (7, 8) and retrospective analyses from clinical
trials (9) have revealed a strong correlation between the intensity
of preconditioning regimens and the efficacy of T-cell therapy.
However, toxicities associated with high-intensity regimens can
be severe and sometimes lethal (10–12). For instance, patients
can experience prolonged leukopenia, increasing the risk for
opportunistic infections. Radiation and chemotherapy are also
associated with increased incidence of thromboembolic events,
including pulmonary venoocclusive disease and thrombotic micro-
angiopathy. Moreover, cortical blindness, a rare toxicity associated
with fludarabine, has been reported in a patient receiving lympho-
depleting chemotherapy before cell transfer (10).
IL-2 is also provided to convey proliferative and survival sig-
nals to transferred cells and enhance their antitumor capacities
(1, 2). Similar to lymphodepleting regimens, high-dose IL-2
is associated with substantial toxicities mainly as a result of a
capillary leak syndrome, which results in a hypovolemic state and
fluid accumulation in the tissues (13).
Because of the potential for severe adverse effects associated
with these maneuvers, numerous patients are excluded from
T-cell therapies because of advanced age, poor performance
status, or a history of cardiovascular and pulmonary diseases. In
addition, management of these toxicities requires extensive sup-
portive care and long-term inpatient hospitalization, placing an
extraordinary financial burden on patients and the healthcare
system. Therefore, the development of novel strategies capable
of substituting the need for lymphodepletion and cytokine sup-
port while maintaining antitumor efficacy is highly desirable.
MicroRNAs (miRs) are 21–23-base-pair-long noncoding RNAs
that modulate gene expression at a posttranscriptional level (14).
Recently, microRNA-155 (miR-155) has emerged as a central
regulator of immune system homeostasis and inflammatory
responses to pathogens and tumors (15, 16). miR-155 is required
for plasma cell differentiation (17) and dendritic cell activity (18). It
has also been shown to regulate Th1 and Th17 lineage commitment
(19). Notably, miR-155 is found to be a key factor regulating Treg
cell homeostasis (20). Finally, miR-155 is required for effector
CD8+ T-cell immune responses against viruses and cancer (21–23).
In this study, we report that overexpression of miR-155 in
tumor-specific CD8+ T cells provides for profound antitumor
responses in the absence of lymphodepletion preconditioning
and cytokine administration. We found that miR-155 enhanced
CD8+ T-cell responsiveness to limited amounts of endogenous
homeostatic cytokines by inhibiting the expression of multiple
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negative regulators of Akt and signal transducer and activator
of transcription 5 (Stat5) signaling, including the inositol 5-
phosphatase Ship1, suppressor of cytokine signaling 1 (Socs1),
and the protein tyrosine phosphatase Ptpn2. These findings in-
dicate that miR-155 can be used to augment the efficacy of T-cell–
based therapies in a cell-intrinsic manner, providing an innovative
approach to circumvent life-threatening maneuvers such as lym-
phodepleting preconditioning and high-dose cytokine support.
Results
miR-155 Enhances CD8+ T-Cell Antitumor Responses in the Absence of
Lymphodepletion and Cytokine Support.We and others have shown
that miR-155 is required for mounting CD8+ T-cell effector
responses against tumors (21, 23). We sought to determine
whether overexpression of miR-155 could enhance the effi-
cacy of T-cell therapy in lymphoreplete hosts without cytokine
support. We transduced pmel-1 T-cell receptor transgenic
CD8+ T cells, which recognize the melanocyte differentiation
antigen gp100, with a γ-retroviral vector encoding miR-155-GFP
(miR-155) or GFP alone as control (Ctrl). T cells were efficiently
transduced, as revealed by the high frequency of cells expressing
GFP (Fig. 1A) and the expression levels of miR-155 (Fig. 1B). We
transferred these cells into C57BL/6 mice bearing a s.c. established
B16 melanoma in conjunction with a recombinant vaccinia virus
encoding gp100 (gp100-VV), which is essential to induce tumor
regression in this model (Fig. S1) (24). Remarkably, we found that
miR-155 cells were capable of inducing profound tumor destruction
in the absence of lymphodepletion, whereas control cells were
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Fig. 1. miR-155 enhances CD8+ T-cell antitumor response by augmenting CD8+ T-cell expansion and effector function in the absence of lymphodepletion and
cytokine support. (A) Frequency of GFP+ cells (numbers above bracketed lines) among pmel-1 CD8+ T cells transduced with retrovirus expressing miR-155-GFP
(miR-155) or GFP alone (Ctrl). (B) RT-PCR analysis of miR-155 expression in cells transduced as in A. (C) Tumor size of C57BL/6 mice bearing B16 tumors
established for 10 d receiving 5 × 106 miR-155 or Ctrl cells in conjunction with gp100-VV. NT, no treatment. (D) Vitiligo of C57BL/6 hosts receiving no cells, Ctrl
miR, or miR-155 cells. (E and F) Flow cytometry (E) and numbers (F) of splenic T cells after adoptive transfer of 106 miR-155 or Ctrl cells into C57BL/6 mice
infected with gp100-VV, assessed 4–35 d after infection. Numbers adjacent to outlined areas indicate percentage of GFP+ T cells after gating on CD8+ cells.
(G and H) Flow cytometry (G) and percentage (H) of transferred T cells within the tumor mass after adoptive transfer of 106 miR-155 or Ctrl cells into tumor-
bearing mice infected with gp100-VV, assessed day 5 and day 7 after infection. Numbers adjacent to outlined areas indicate percentage of CD8+GFP+ T cells.
(I) Intracellular cytokine staining of GFP+ CD8+ T cells isolated from the spleen after the adoptive transfer of miR-155 or Ctrl cells. Numbers in quadrants
indicate percentage of IFN-γ+, TNF-α+, and IFN-γ+ TNF-α+ after gating on GFP+ CD8+ cells. (J) Pie charts depicting the quality of the cytokine response in GFP+
CD8+ T-cell of three mice, as determined by the Boolean combination of gates identifying IFN-γ+, IL-2+, and TNF-α+ cells. (K) Percentage of cytokine-producing
cells in the spleen of mice transferred with miR-155 or Ctrl cells. *P < 0.05, **P < 0.01, ****P < 0.0001 (a two-tailed Student t test). Data are representative of
two independent experiments [error bars (B), SEM of three samples; error bars (C, D), SEM of four two five samples; error bars (F, H, and K), SEM of three to
four samples].
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almost completely ineffective (Fig. 1C). Similar findings were ob-
served using scrambled miR-GFP (Ctrl miR) as control, excluding
potential nonspecific effects resulting from the displacement of
endogenous miRNAs by overexpressed miR-155 (Fig. S2). With the
exception of autoimmune vitiligo (Fig. 1D), a well-characterized on-
target toxicity (24), there were no discernable acute adverse events
in mice receiving miR-155 cells (Fig. S3A). Because miR-155 dys-
regulation has been linked to tumor development (25), we moni-
tored mice engrafted with miR-155 or Ctrl cells during a period of
up to 747 d. There were no differences in the incidence of cellular
transformation in mice receiving miR-155 compared with Ctrl cells
(Fig. S3B).
To investigate the cellular basis behind the enhanced antitu-
mor activity of miR-155 cells, we measured the expansion and
function of adoptively transferred miR-155 or Ctrl cells after
gp100-VV vaccination. Ctrl cells displayed a prototypical re-
sponse characterized by a rapid expansion phase that peaked
4 d after immunization, followed by a profound contraction, which
resulted in a small fraction of surviving cells by day 7 (Fig. 1 E
and F). Although miR-155 cells expanded similarly, their con-
traction was substantially delayed (Fig. 1 E and F). Similar
findings were also observed within the tumor mass (Fig. 1 G and
H). Notably, we did not observe differences in cell numbers at
the memory phase of the immune response, indicating that miR-
155 overexpression did not result in unrestrained expansion (Fig.
1F). Strikingly, miR-155 cells also exhibited increased poly-
functionality and sustained ability to secrete IL-2, TNF-α, and
IFN-γ overtime compared with Ctrl cells, which rapidly became
functionally exhausted after the peak of the immune response
(Fig. 1 I–K). These findings indicate that miR-155 augments
CD8+ T-cell antitumor responses by enhancing both cell survival
and effector function in the absence of lymphodepletion.
miR-155 Enhances T-Cell Function Under Conditions of Limited Cytokine
Availability. We sought to determine whether the antitumor
activity of miR-155 cells could be further enhanced in tumor-
bearing hosts rendered lymphopenic by 6 Gy total body irradi-
ation. Consistent with previous findings (6), this preconditioning
regimen potentiated the therapeutic efficacy of Ctrl pmel-1 cells,
resulting in prolonged survival of tumor-bearing mice (Fig. 2 A
and C). Surprisingly, miR-155 cells displayed similar antitumor
efficacy in lymphoreplete and lymphodepleted hosts (Fig. 2 B
and D), although vitiligo was less pronounced in the lympho-
replete setting (Fig. S4).
Because miR-155 is induced on T-cell activation (21), there
was the possibility that the activating cues present in lympho-
depleted hosts could up-regulate endogenous miR-155 levels in
Ctrl cells, thus enhancing their antitumor activity, whereas the
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Fig. 2. miR-155 antitumor activity is not enhanced by lymphodepletion or
exogenous homeostatic γc cytokines. (A and B) Tumor size of C57BL/6 mice
bearing B16 tumors established for 10 d receiving 5 × 106 Ctrl (A) or miR-155
(B) cells in conjunction with gp100-VV with/without a sublethal dose of 6-Gy
lymphodepletion. (C and D) Survival of mice treated with Ctrl (C) or miR-155
(D) cells described in A and B. (E and F) Tumor size of C57BL/6 mice bearing
B16 tumors established for 10 d receiving 5 × 106 Ctrl (E) or miR-155 (F) cells
in conjunction with gp100-VV with/without a high dose of IL-7 and IL-15
administration. (G and H) Survival of mice treated with Ctrl (G) or miR-155
(H) cells described in E and F. NT, no treatment. **P < 0.01 [A Log-rank
(Mantel-Cox) test]. Data are representative of two independent experiments
(error bars, SEM of five samples).
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Fig. 3. Endogenous IL-7 and IL-15 are required to support the enhanced
functionality of miR-155 overexpressing cells. (A) Numbers of cytokine pro-
ducing CD8+ GFP+ cells isolated from the spleen of WT, Il15−/−, and Il7−/−
Il15−/− hosts after the adoptive transfer of Ctrl or miR-155 cells in conjunction
with gp100-VV at indicated points after infection. (B) Numbers of the poly-
functional CD8+GFP+ cells isolated from the spleen of WT, Il15−/−, and Il7−/−
Il15−/− hosts after the adoptive transfer of Ctrl or miR-155 cells in conjunction
with gp100-VV at day 7 after infection. (C and D) Tumor size of WT or Il7−/−
Il15−/−mice bearing B16 tumors established for 10 d receiving 2 × 106 Ctrl (C)
or miR-155 (D) cells in conjunction with gp100-VV. NT, no treatment. *P <
0.05, **P < 0.01 (a two-tailed Student t test). Data are representative of two
independent experiments [error bars (A and B), SEM of three to four sam-
ples; error bars (C and D), SEM of four to five samples].
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efficacy of miR-155 cells could not be further boosted in the
setting of lymphodepletion because overexpression of miR-155
had driven the biological activity to plateau. However, lym-
phodepletion preconditioning did not cause up-regulation of
endogenous miR-155 (Fig. S5A). In contrast, miR-155 levels
increased in miR-155 cells in the setting of lymphodepletion,
a finding consistent with the notion that lymphocyte activation
augments transgene expression (26).
A major mechanism behind the increased efficacy of tumor-
specific T cells in the lymphopenic environment is the removal of
CD4+ Treg cells (3, 4). We therefore hypothesized that miR-155
might enable CD8+ T cells to overcome Treg cell suppression.
However, in our model system, CD4+ T cells appeared to play
a minor role, as pmel-1 cells demonstrated similar antitumor
responses in wild-type (WT) or Cd4−/− hosts (Fig. S5B).
Lymphodepletion also increases the availability of homeostatic
cytokines to adoptively transferred T cells by removing endoge-
nous cytokine sinks (6). We sought to determine whether miR-
155 enhanced CD8+ T-cell responsiveness to cytokines in lym-
phoreplete hosts, which have limited availability of homeostatic
cytokines. We transferred miR-155 or Ctrl pmel-1 cells into B16
tumor-bearing mice, together with gp100-VV, in the presence or
absence of high doses of the homeostatic cytokines IL-7 and
IL-15. Consistent with previous data (6), provision of these
cytokines increased the therapeutic efficacy of Ctrl cells and
improved animal survival (Fig. 2 E and G). In sharp contrast, we
did not observe additional benefits in mice receiving miR-155
cells (Fig. 2 F and H), suggesting the limited amounts of ho-
meostatic cytokines available in lymphoreplete hosts are suf-
ficient to promote the potent immune response mediated by
miR-155 cells.
To test whether homeostatic cytokines were required for the
enhanced functionality of miR-155 cells, we evaluated the kinetic
of the immune response in mice deficient in IL-7 and IL-15. We
transferred miR-155 or Ctrl cells in conjunction with gp100-VV
into WT, Il15−/−, and Il7−/− Il15−/− hosts and enumerated the
number of cytokine-producing pmel-1 cells. Recapitulating ear-
lier findings, overexpression of miR-155 increased the number of
functional cells compared with Ctrl in WT recipients. However,
the number of functional miR-155 cells was reduced in Il15−/−
hosts and was more severely decreased in mice lacking both
homeostatic cytokines (Fig. 3A). Moreover, the sustained
polyfunctionality observed in miR-155 cells in WT hosts was
severely impaired in Il7−/− Il15−/− mice (Fig. 3B). To determine
whether IL-7 and IL-15 were essential for the increased antitu-
mor response of miR-155 cells, we transferred miR-155 or Ctrl
pmel-1 cells in conjunction with gp100-VV into WT or Il7−/−
Il15−/− mice bearing B16 melanoma. We found that the antitu-
mor efficacy of miR-155 cells was significantly decreased in Il7−/−
Il15−/− mice, indicating that benefit provided by miR-155 was de-
pendent on homeostatic cytokine signaling (Fig. 3 C and D). Taken
together, these results suggest that the presence of homeostatic γc
cytokines is essential for the enhanced activity of miR-155 cells.
miR-155 Inhibits Multiple Negative Regulators of Akt and Stat5 Signaling.
We sought to dissect the molecular mechanisms behind the in-
creased efficacy of miR-155 cells in conditions where homeo-
static cytokines are limiting. Because miR-155 does not affect the
expression of the IL-15 and IL-7 receptor complexes (21), we
focused on downstream signaling. It is well established that γc
cytokines primarily signal through three pathways: Mapk, Jak3/
Stat5, and PI3K/Akt (27). To determine whether any of these
pathways were modulated by miR-155 overexpression, we eval-
uated the amount of phosphorylated Mapk1, Akt, and Stat5 in
miR-155 and Ctrl cells. Strikingly, we detected increased pAkt
and pStat5 in miR-155 cells, but no major differences in pMapk1
(Fig. 4A). It has been recently reported that Stat1 signaling is
enhanced in CD8+ T cells lacking miR-155 (22); however, we did
not observe noticeable differences in pStat1 levels in miR-155
compared with Ctrl cells (Fig. S6). Ship1, a negative regulator of
Akt signaling, is an established miR-155 target (28). Consistently,
we detected decreased levels of Ship1 in miR-155 compared with
Ctrl cells, thus providing a mechanistic basis for the observed
enhancement in Akt activity (Fig. 4B). Previously, we have dem-
onstrated that miR-155 regulates Stat5 signaling by targeting the
suppressor of cytokine signaling, Socs1 (21). Here, we noted that
Socs1 levels were decreased in miR-155 cells (Fig. 4C).
Bioinformatic analysis by TargetScan predicted an evolution-
arily conserved miR-155 binding site at the 3′ UTR region of
Ptpn2 (Fig. 4D). Ptpn2 is a negative regulator of Jak3/Stat5
signaling that has been shown to restrain homoeostatic T-cell
responses (29). Furthermore, knockdown of PTPN2 in human
T-cell acute lymphoblastic leukemia increased the proliferation
and cytokine sensitivity of leukemic cells (30), a phenotype
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Fig. 4. miR-155 inhibits multiple negative regulators
of Akt and Stat5 signaling. (A–C) Immunoblot analy-
ses of miR-155 or Ctrl cells, probed with anti-pMapk1
(A, Left), anti-pAkt (A, Middle), anti-pStat5 (A, Right),
anti-Ship1 (B), and anti-Socs1(C). Gapdh (A and B) and
β-actin (C) were used as loading controls. (D) Multiple
species sequence alignment of the Ptpn2 3′ UTR, in-
cluding the predicted miR-155 target site sequence
(bold). Mutations of the miR-155 target sites are
shown below. (E) HEK293T cells were cotransfected
with WT or mutated Ptpn2 3′ UTR and miR-155 mimic
or control scrambled miR mimic and assessed for lu-
ciferase activity 24 h after transfection. (F) Immuno-
blot analyses of cells prepared as in A, probed with
anti-Ptpn2 and anti-Gapdh. (G and H) Flow cytometry
(G) and relative levels of pStat5 (H) in CD8+ T cells
coexpressing miR-155/scrambled miR and Ptpn2/Thy-
1.1. *P < 0.05, ****P < 0.0001 (a two-tailed Student t
test). Data are representative of two independent
experiments [error bars (E), SEM of three to four
samples] or four independent experiments (G and H).
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closely resembling the effects of miR-155 overexpression in our
model. Thus, we sought to test whether miR-155 directly
regulates Ptpn2. We transfected HEK293T cells with luciferase
reporter constructs containing the Ptpn2 3′ UTR with an intact
or mutated miR-155 binding sequence together with miR-155 or
a Ctrl miR. Cotransfection of Ptpn2 3′ UTR with miR-155
resulted in a significant repression of reporter activity, whereas
mutation of the miR-155 seed-binding site abolished this re-
pression (Fig. 4E). These findings indicate that miR-155 directly
regulates Ptpn2 expression. Next, we evaluated Ptpn2 protein
levels in miR-155 cells. Consistently, we detected a substantial
decrease of Ptpn2 by Western blot (Fig. 4F), indicating that
Ptpn2 is targeted by miR-155. To determine whether down-
regulation of Ptpn2 was relevant to the enhanced Stat5 signaling
mediated by miR-155 overexpression, we measured pStat5 in
miR-155 cells in the presence of ectopic expression of Ptpn2.
Overexpression of Ptpn2 significantly reduced pStat5 levels in
miR-155 cells (Fig. 4 G and H), suggesting that modulation of
Ptpn2 contributes to the functional advantage mediated by miR-
155. Altogether, these findings reveal that miR-155 enhances Akt
and Stat5 signaling in a cell-intrinsic manner by repressing multiple
negative regulators of these pathways in CD8+ T cells.
Akt and Stat5 Signaling Contribute to the Functional Advantage
Conferred by miR-155. Having demonstrated that miR-155 pro-
moted Akt and Stat5 signaling, it remained to be determined
whether either or both pathways contribute to the enhanced
CD8+ T-cell functionality mediated by miR-155 overexpression.
We cotransduced pmel-1 cells with Ctrl or miR-155, together
with a constitutively active form of Akt (AktCA) or Stat5
(Stat5aCA) (Fig. 5A), and tracked the fate of double-transduced
cells by monitoring the reporter markers GFP (miR-155 or Ctrl)
and Thy1.1 (AktCA, Stat5aCA, or Ctrl) after adoptive transfer
into WT hosts in conjunction with gp100-VV (Fig. 5A). Because
Stat5 signaling has been shown to induce miR-155 (31), we first
tested the expression of miR-155 in Stat5aCA cells. We found
that although Stat5aCA up-regulated miR-155 expression, its
levels were far below the amounts detected in miR-155 cells (Fig.
S7). Importantly, AktCA did not influence the endogenous ex-
pression of miR-155 (Fig. S7). Next, we evaluated the effects of
AktCA and Stat5aCA on miR-155 cells by assessing the numbers
and function of transduced cells 7 d after transfer, the time at
which the differences between miR-155 and Ctrl cells are most
prominent (Figs. 1 E–K and 3 A and B). Overexpression of
Stat5aCA, but not AktCA, reduced the differences in cell
numbers between miR-155 and Ctrl cells, as demonstrated by
percentage and ratios, indicating functional redundancy between
miR-155 and Stat5aCA in delaying contraction kinetics (Fig. 5 B
and C). In contrast, overexpression of AktCA significantly re-
duced the differences in cell functionality between miR-155 and
Ctrl cells, suggesting miR-155 promoted sustained cytokine
production through the activation of Akt (Fig. 5 D and E). Al-
together, these findings indicated that Stat5 and Akt play non-
redundant and distinctive roles in driving miR-155-mediated
numeric and functional advantages.
Discussion
In this study, we report a strategy to eliminate the need for
preparative lymphodepleting regimens as well as the adminis-
tration of exogenous cytokines in adoptive immunotherapy.
Overexpression of miR-155 in tumor-specific CD8+ T cells en-
hanced their responsiveness to limited amounts of cytokines
present in lymphoreplete hosts in a cell-intrinsic manner, resulting
in increased survival and sustained functionality. These findings
have parallels in CD4+ T cells, where miR-155 is essential for long-
term maintenance of Treg cells in lymphoreplete, but not lympho-
depleted, mice (20). Other strategies to potentiate adoptive T-cell
therapy in the absence of lymphodepletion have been recently
proposed, such as PD1 blockade in the presence of IL-2/anti-IL-2
antibody complexes (32) or overexpression of IL-12 in tumor-
reactive T cells (33). However, it is unclear whether such
approaches can replace both lymphodepletion and cytokine
support. For instance, overexpression of IL-12 in pmel-1 cells
could not substitute the requirement for lymphodepletion in
this model of T-cell therapy (34). Here, we demonstrate that
total body irradiation preconditioning or high-doses of exog-
enous cytokines could not increase the treatment efficacy of
miR-155 cells, indicating that overexpression of miR-155 is
sufficient in surrogating the therapeutic advantages conveyed
by these regimens. Although miR-155 overexpression promoted
vitiligo, the severity of this adverse effect was significantly re-
duced compared with Ctrl cells transferred into lymphodepleted
hosts, making this therapeutic strategy even more attractive.
By dissecting the molecular mechanism behind the activity of
miR-155 overexpression, we discovered that miR-155 enhanced
Akt and Stat5 signaling by suppressing multiple negative regu-
lators of these pathways. We confirmed that miR-155 targets the
Akt inhibitor, Ship1, as well as Socs1, a well-established Stat5
inhibitor. Moreover, we identified Ptpn2 as a novel target of
miR-155 and demonstrated that down-regulation of this mole-
cule is relevant to the modulation of Stat5 signaling mediated by
miR-155. Intriguingly, increased Stat5 signaling appears to con-
tribute primarily to cell survival, whereas enhanced Akt signaling
seems mainly responsible for sustained functionality mediated by
miR-155 overexpression. Enhancing the activity of both Akt and
Stat5 by modulating miR-155 expression provides advantages
over strategies relying on constitutive activation of these two
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Fig. 5. Akt and Stat5 signaling contribute to the functional advantage
conferred by miR-155. (A) Experimental layout used to dissect the dis-
tinctive contribution of Stat5 or Akt signaling in miR-155 cells. (B) Flow
cytometry of splenic T cells after adoptive transfer of 3 × 105 FACS
sorted pmel-1 CD8+GFP+Thy-1.1+ T cells (transduced as in A) into C57BL/
6 mice infected with gp100-VV, assessed at day 7 after infection. Num-
bers adjacent to outlined areas indicate percentage of GFP+Thy-1.1+ T
cells after gating on CD8+ cells. (C ) Ratio of miR 155 to Ctrl cells
cotransduced with Stat5aCA, AktCA, or Ctrl Thy-1.1 isolated from the
spleen of C57BL/6 mice, as described in B. (D) Pie charts depicting the
quality of the cytokine response in CD8+GFP+Thy-1.1+ T cells treated as
in B. (E ) Ratio of miR 155 to Ctrl cytokine producing cells from pmel-1
CD8+GFP+Thy-1.1+ T treated as in B. *P < 0.05, ****P < 0.0001 (a two-
tailed Student t test). Data are representative of two independent
experiments [error bars (C and E ), SEM of three to four samples).
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pathways, as it allows fine-tuning of multiple cellular processes
by targeting numerous molecules without the negative effects
that can be associated with a strong constitutive activation of
a single pathway. For instance, constitutive Akt activation can
drive cells toward terminal differentiation, impairing their long-
term survival (35). This represents a clear disadvantage, as per-
sistence of transferred cells correlates to antitumor responses in
preclinical mouse models (36, 37) and clinical trials (9, 38).
Although we did not observe increase rates of malignant
transformation of miR-155 cells (Fig. S3B), the potential onco-
genicity of miR-155 warrants cautions and might require the
introduction of suicide genes to enable the elimination of
transferred cells if transformation occurs (39). Alternatively,
inducible promoters might be used to control the expression
of miR-155. For example, an NFAT-responsive promoter has
been successfully used to limit the toxicities associated with
constitutive expression of IL-12 (40).
Lymphodepleting preconditioning regimens and administra-
tion of high doses of cytokines are currently used in the clinic to
augment the therapeutic efficacy of T-cell therapies (1, 2), but
the toxicities associated with these maneuvers and the high costs
of patient supportive care prevent access and widespread adop-
tion of these treatments worldwide. Moreover, the requirement
of preparative therapies before T-cell transfer excludes the
possibility of multiple rounds of T-cell administration at short
intervals, as repeated rounds of preconditioning treatments
are not feasible. Enforced expression of miR-155 in tumor-
reactive T cells would not only overcome the requirement for
use of nonspecific modalities such as chemotherapy or total
body irradiation, with associated life-threatening adverse
effects, but also might allow short-term repetitive T-cell ad-
ministration to achieve optimal therapeutic outcomes.
Materials and Methods
All mouse experiments were approved by the National Cancer Institute Animal
Use and Care Committee. Real-time RT-PCR, immunoblot, retrovirus production,
transduction of CD8+ T cells, adoptive cell transfer, infection, and tumor treat-
ment were previously described (21, 37). Luciferase reporter assay was per-
formed using LightSwitch Luciferase Assay Kit (Switchgear Genomics) according
to the manufacturer’s protocol. Detailed information about mice, experimental
procedures and statistical analyses can be found in SI Materials and Methods.
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